Formosa Laboratories, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2020
November 11, 2020 at 12:06 pm EST
Share
Formosa Laboratories, Inc. announced earnings results for the third quarter ended September 30, 2020. For the third quarter, the company announced sales was TWD 814.723 million compared to TWD 789.583 million a year ago. Net income was TWD 100.894 million compared to TWD 171.789 million a year ago. Basic earnings per share was TWD 0.93 compared to TWD 1.74 a year ago. Diluted earnings per share was TWD 0.85 compared to TWD 1.56 a year ago. For the nine months, sales was TWD 2,265.073 million compared to TWD 2,037.950 million a year ago. Net income was TWD 533.187 million compared to TWD 84.988 million a year ago. Basic earnings per share was TWD 5.09 compared to TWD 0.86 a year ago. Diluted earnings per share was TWD 4.6 compared to TWD 0.82 a year ago.
Formosa Laboratories, Inc. is a Taiwan-based company principally engaged in the development, production and distribution of ultraviolet (UV)-proof active ingredients, bulk pharmaceutical chemicals, antibody drug conjugates, as well as the provision of customized services. The Company primarily provides UV-proof active ingredients series products, vitamin D derivative series products, anti-inflammatory analgesic series products, steroid, anti-cancer drugs, cholesterol phosphate binding agents, nuclear magnetic resonance (NMR) reagents, respiratory disease drugs, central nervous system drugs, immune system regulators and weight loss drugs, as well as customized research and development and original equipment manufacturing (OEM) services. The Company distributes its products to Europe, the Americas, Asia and other markets.
FORMOSA LABORATORIES, INC. 
